Ganciclovir for Injection, USP, 500mg per vial, packaged in a 10-count carton, Rx Only, Mfd. by: ...
FDA Drug Recall #D-0090-2023 — Class II — December 16, 2022
Recall Summary
| Recall Number | D-0090-2023 |
| Classification | Class II — Moderate risk |
| Date Initiated | December 16, 2022 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Hikma Pharmaceuticals USA Inc. |
| Location | Cherry Hill, NJ |
| Product Type | Drugs |
| Quantity | 13,760 vials |
Product Description
Ganciclovir for Injection, USP, 500mg per vial, packaged in a 10-count carton, Rx Only, Mfd. by: THYMOORGAN PHARMAZIE GmbH, Germany, Distributed by Hikma Berkeley Heights, NJ 07922, NDC 0143-9299-01
Reason for Recall
Labeling: Label mix-up - one vial was mislabeled as Cladribine Injection 10mg/mL inside a 10-count carton of Ganciclovir 500 mg.
Distribution Pattern
USA Nationwide
Lot / Code Information
Lot#: BQ0006, Exp 08/2023
Other Recalls from Hikma Pharmaceuticals USA Inc.
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0551-2025 | Class II | Lorazepam Injection, USP, 2 mg/mL, 25 x 1mL via... | Jul 22, 2025 |
| D-0635-2024 | Class I | Acetaminophen Injection, 1,000 mg per 100 mL (1... | Jul 8, 2024 |
| D-0392-2024 | Class II | Infumorph (Preservative-free Morphine Sulfate S... | Mar 12, 2024 |
| D-0574-2023 | Class II | Lorazepam Injection, USP, 2mg/mL, 1 mL vial (ND... | May 11, 2023 |
| D-1309-2022 | Class II | Lorazepam Injection, USP, 2mg/mL, 1 mL vial, 2... | Jul 11, 2022 |
Frequently Asked Questions
Stop using the medication immediately and contact your pharmacist. A mislabeling recall can range from a minor technical error (wrong font size) to a serious mix-up where one drug is inside another drug's packaging. If you received a medication that looks or acts differently than expected, or if you experienced unexpected effects, tell your doctor immediately. The pharmacist can verify whether your specific lot is affected and provide a replacement. Report any adverse effects experienced to FDA MedWatch at 1-800-FDA-1088.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.